Women with high-risk HPV had an increased risk for CVD, especially in those with metabolic syndrome and obesity, according to a study published in Circulation Research.
“A better understanding of high-risk HPV as a risk factor for cardiovascular disease and possible combined effects of high-risk HPV, obesity and metabolic syndrome in increasing cardiovascular disease risk may help improve preventive strategies and patient outcomes,” Seungho Ryu, MD, PhD, professor at Kangbuk Samsung Hospital at Sungkyunkwan University School of Medicine in Seoul, South Korea, said in a press release.
Eun-Jeong Joo, MD, PhD, of the division of infectious diseases at Kangbuk Samsung Hospital at Sungkyunkwan University School of Medicine, and colleagues analyzed data from 63,411 women (mean age, 40 years; mean BMI, 22 kg/m2) without CVD at baseline from the Kangbuk Samsung Health Study.
Women completed questionnaires to collect information on demographics, alcohol consumption, smoking status, education level, physical activity, family history of CVD and medical history of CVD or cancer. Physical examinations were also performed to measure BP, height and weight, in addition to collect blood samples and conduct high-risk HPV tests.
The primary outcome of interest was incident CVD, defined as the first diagnosis for CVD including stroke, ischemic heart disease and transient ischemic attack. Follow-up was conducted for 261,598.9 person-years and a median duration of 4.4 years.
Of the women in the study, 7.6% had high-risk HPV. During follow-up, 1,122 cases of new-onset CVD were diagnosed with an incidence rate of 4.3 per 103 person-years.
After adjusting for age, the HR for women who were high-risk HPV-positive vs. those who were high-risk HPV negative was 1.26 (95% CI, 1.03-1.53). A significant relationship between HPV and CVD persisted after adjusting for possible confounders and high-sensitivity C-reactive protein (HR = 1.25; 95% CI, 1.03-1.52). This association was stronger in women with obesity (P for interaction = .02) and metabolic syndrome (P for interaction = .05).
Women with high-risk HPV and without obesity had an increased risk for incident CVD vs. those without high-risk HPV (HR = 1.1; 95% CI, 0.87-1.39). The risk then increased in women with high-risk HPV and obesity (HR = 1.73; 95% CI, 1.19-2.51). Similar results were seen in women without metabolic syndrome (HR = 1.09; 95% CI, 0.87-1.36) and those with metabolic syndrome (HR = 1.99; 95% CI, 1.28-3.08).
“This suggests that high-risk HPV might affect CVD risk when accompanied by obesity or [metabolic syndrome],” Joo and colleagues wrote. “Further studies are required to identify the specific high-risk HPV genotypes that may contribute to CVD and implement vaccine strategies as a modifiable risk factor for the reduction of CVD in addition to prevention of anogenital cancers.” – by Darlene Dobkowski
Disclosures: The authors report no relevant financial disclosures.